Deputy Chief Physician of VIP-II Department, Peking University Cancer Hospital. Graduated from Peking University Health Science Center and previously visited Cardiff University School of Medicine in the UK for academic exchange. Specializes in medical pharmacotherapy for digestive system tumors, including esophageal cancer, gastric cancer, colorectal cancer, liver cancer, bile duct cancer, and pancreatic cancer, utilizing treatments such as chemotherapy, targeted therapy, and immunotherapy. Has led or participated in the completion of multiple National Natural Science Foundation of China projects, such as "Molecular mechanism of Noggin promoting gastric cancer proliferation through the β-catenin/EGFR/Akt pathway." Has published several SCI articles on gastrointestinal tumors, including "Increased Expression of Gremlin1 Promotes Proliferation and Epithelial Mesenchymal Transition in Gastric Cancer Cells and Correlates With Poor Prognosis of Patients With Gastric Cancer" and "Association between polymorphisms of ABCB1 and prognosis in esophageal squamous cell carcinoma patients treated with taxane."